Breast cancer therapy frequently employs chemotherapeutic drugs as neoadjuvants. However, a substantial body of evidence suggests that a majority of patients experience treatment failure as a result of developing resistance. Cancer stem cells, which constitute a minority of cells inside tumor masses, play a significant role in conferring resistance to cancer treatments, facilitating tumor recurrence, and promoting the spread of cancer cells to distant sites. Consequently, the development of therapeutic approaches specifically targeting breast cancer stem cells represents a key avenue for effectively addressing chemoresistance. I am currently investigating the molecular mechanisms underlying chemoresistance and endeavoring to design a therapeutic drug capable of overcoming this phenomenon by using genomics, transcriptomics, proteomics, and metabolomics approaches.